2.90
0.01 (0.35%)
| Previous Close | 2.89 |
| Open | 2.92 |
| Volume | 1,174,345 |
| Avg. Volume (3M) | 1,918,796 |
| Market Cap | 973,144,384 |
| Price / Sales | 361.31 |
| Price / Book | 2.99 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -32,779.44% |
| Diluted EPS (TTM) | -2.22 |
| Total Debt/Equity (MRQ) | 2.76% |
| Current Ratio (MRQ) | 11.49 |
| Operating Cash Flow (TTM) | -84.21 M |
| Levered Free Cash Flow (TTM) | -290.49 M |
| Return on Assets (TTM) | -54.37% |
| Return on Equity (TTM) | -88.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Nuvation Bio Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | 0.75 |
|
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 27.01% |
| % Held by Institutions | 43.98% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2024 | 25,954,439 |
| Ecor1 Capital, Llc | 30 Sep 2024 | 19,209,643 |
| Omega Fund Management, Llc | 30 Sep 2024 | 13,072,340 |
| Redmile Group, Llc | 30 Sep 2024 | 3,031,009 |
| Aisling Capital Management Lp | 30 Sep 2024 | 2,541,009 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (HC Wainwright & Co., 141.38%) | Buy |
| Median | 6.00 (106.90%) | |
| Low | 5.00 (Wedbush, 72.41%) | Buy |
| Average | 6.00 (106.90%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 2.70 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 07 Nov 2024 | 6.00 (106.90%) | Buy | 2.62 |
| Wedbush | 22 Oct 2024 | 5.00 (72.41%) | Buy | 2.41 |
| 11 Sep 2024 | 5.00 (72.41%) | Buy | 3.07 | |
| HC Wainwright & Co. | 16 Sep 2024 | 7.00 (141.38%) | Buy | 3.07 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 26 Nov 2024 | Announcement | Nuvation Bio to Present at the 7th Annual Evercore ISI HealthCONx Conference |
| 12 Nov 2024 | Announcement | Nuvation Bio to Present at the Jefferies London Healthcare Conference |
| 06 Nov 2024 | Announcement | Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update |
| 07 Oct 2024 | Announcement | Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer |
| 14 Sep 2024 | Announcement | Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 |
| 09 Sep 2024 | Announcement | Nuvation Bio to Present at the Cantor Global Healthcare Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |